Skip to content

QLT obtains orphan drug designation for retinitis pigmentosa treatment

QLT Inc., a Canadian based biotechnology company, has announced that its oral synthetic retinoid product for the treatment of retinitis pigmentosa has been granted orphan drug designation. The drug had previously obtained orphan drug designation from the FDA for the treatment of Leber’s Congenital Amaurosis (LCA).